Incyte (INCY) PT Raised to $112 at Oppenheimer on Pemazyre Noting 5 Upcoming Catalysts
Tweet Send to a Friend
Oppenheimer analyst Jay Olson raised the price target on Incyte (NASDAQ: INCY) to $112.00 (from $90.00) after Pemazyre (pemigatinib) was ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
